Key Takeaways
- Custom synthesis momentum is the core story: A second long-term supply agreement in two years, a healthy RFP pipeline, and two new projects targeting commercialization by late 2026/early 2027 signal a multi-year growth vector.
- Generic business holds ground in a tough market: Volumes stayed stable despite persistent pricing headwinds and high competitive intensity, with leadership sustained through process innovation.
- Kakinada backward integration goes live: Production started in January, with Phase-I nearing completion; the primary payoff is supply security for critical raw materials, with margin benefits accruing over time.
- Peptide investments are scaling ahead of demand: Dual capability in solid-phase and liquid-phase synthesis is built out, with customer engagements across multiple phases, though management stayed silent on GLP-1 specifics.
- What to watch next quarter: Whether the double-digit revenue growth guidance for FY26 materializes in Q1, any quantification of Kakinada's margin contribution, and progress on the two new custom synthesis projects.
Custom Synthesis: The Growth Engine
- Second major deal in two years: A long-term manufacturing and supply agreement for an advanced intermediate was signed with a leading global pharma company, following the ~₹700 crores API deal announced in April 2024. Both are custom synthesis projects.
- Pipeline depth is real but opaque: Several products are in the pipeline across R&D and pilot scales; management cited confidentiality as the reason for not quantifying the opportunity, but confirmed healthy RFP uptick and regular customer site visits.
- Two new projects with a timeline: The newly announced projects carry a combined CAPEX of ₹700-800 crores, with commercialization expected by late 2026 or early 2027, subject to customer regulatory approvals.
- Sales cycles are long and variable: From RFP to commercialization can range from 1.5-2 years in aggressive cases to 6-7 years, depending on molecule phase, regulatory approvals, and customer timelines.
- Reshoring is not changing the conversation: When asked about large US pharma companies announcing reshoring manufacturing capex, management did not address any shift in customer behavior, stating only that Divi's has always been in the CS business and RFQs come continuously.
Dr. Kiran S. Divi: "It's not something that we started after China Plus One or the Biosecure Act has started, our business was there. We've been in this business even before anyone has ever been in it."
Kakinada: Supply Security First, Margin Later
- Phase-I is operational: Production started in January across 7 production blocks on 200 of 500 acres; backward-integrated material has slowly entered products, with about ₹200 crores of remaining CAPEX to complete Phase-I.
- The primary purpose is supply continuity: Management was explicit that Kakinada's main reason is continuous supply of own raw materials and critical starting materials, not just pricing or impurity profile control, though those are secondary benefits.
- Margin impact is deliberately unquantified: When asked if Kakinada has already started helping gross margins or would take a couple of quarters to become EBITDA-neutral, management declined to look at Kakinada as a single unit and said to assess the molecule as a whole.
- Phase-II is contingent on demand: No plans yet for Phase-II construction on the remaining 300 acres; expansion will depend on market opportunities as they arise.
- Strategic real estate play: Kakinada frees up existing blocks in Unit-I and Unit-II for GMP product manufacturing while Kakinada itself goes through its own regulatory phase.
Dr. Kiran S. Divi: "Kakinada more than creating space or controlling our price, the main reason of having Kakinada is for having continuous supply of our own raw materials and our critical starting materials."
Generic Business: Volume Resilience Under Price Pressure
- Pricing headwinds persist: Competitive intensity remains high in the generic business, but stable volumes were maintained across all core products through process innovation and operational efficiency.
- New molecule strategy is steady-state: As new molecules come off-patent, Divi's will start producing them and slowly build market share; management did not call out any blockbuster near-term generic opportunity.
- GLP-1 generics are off the table: Management stated it is not looking at working with GLP-1s in the generic space, focusing instead on innovative molecules with innovators, citing confidentiality on specific programs.
- Margin attribution was sidestepped: When an analyst asked whether strong generic growth was driven by price rise and its contribution to margins, management answered about competition and market share without directly addressing the price or margin question.
Dr. Kiran S. Divi: "See, as of now, I am bound by confidentiality. It is whether I am producing for innovator, I mean, based on our knowledge, knowhow and everything, we believe we are best suited now to work on innovative molecules in the GLP space."
Peptides & New Modalities: Building Before the Boom
- Dual-platform investment complete: Divi's has actively invested in both solid-phase and liquid-phase peptide synthesis capabilities, positioning to serve global demand for novel peptide-based therapies including GLP-1s, GIPs, and GLP-2 analogs.
- Customer engagements are underway: The company is working with several customers at various phases and can support requirements as and when needed with the investments already made.
- ADCs and nucleotides are too early: Management said these areas are still in preliminary phases and declined to comment further.
- CAPEX is not ring-fenced for GLP-1s: When asked about capital investment specifically for GLP-1s, management deflected, stating equipment could be used for APIs, custom products, or GLP-1s and has not been classified separately.
- Next-generation technologies added: Continuous Flow Chemistry and Biocatalysis were identified as new avenues of growth from the latest announcement.
Margins & Supply Chain: Favorable but Fragile
- Q4 exit rate is a two-year high: Gross margin and EBITDA margin exit rate for Q4 was one of the strongest over the last two-year period, driven mainly by product mix which changes quarter-on-quarter; management recommends annual assessment.
- Other expenses fell sharply: Other expenses as a percentage of sales dropped from 17% to 14% despite 18% growth, driven by multiple factors including higher repairs on older plant and machinery, increased freight and travel expenditures, and environment management expenses; management could not pinpoint a single driver.
- Raw material environment is benign: Relative stability in raw material pricing this quarter, with multi-source procurement across US, EU, Middle East, Asia and domestic sources ensuring consistent availability; favorable conditions expected to persist over the next two quarters.
- Red Sea disruptions are managed, not resolved: Rerouting around the Cape of Good Hope extended inbound lead times by two to three weeks from US and Europe, while outbound shipping times and freight costs to EU, US, and Latin America remain elevated; sea freight rates are expected to stay broadly stable in Q1 FY26.
- Inventory is normalizing toward lean: Inventory has stayed around ₹3,000 crores despite highest-ever sales, attributed to easing raw material availability and a shift away from crisis-driven stocking; management's aspiration is to move toward just-in-time sourcing, though this depends on product mix and source availability.
Nilima Prasad Divi: "But if you ask me what my wishful thinking is, I would love to maintain a lean inventory. I wouldn't want to have lot of inventory stocks, I would definitely want to have a lean inventory wherein I can implement more of just in time and have it just source what I am manufacturing at that point in time."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Revenue growth | Double-digit growth for the organization overall | FY26 and next few years |
| New CS project commercialization | Two projects (₹700-800 crores CAPEX) commercialized, subject to customer regulatory approvals | Late 2026 or early 2027 |
| Kakinada Phase-I completion | ~₹200 crores remaining CAPEX to be spent | Not specified |
| Annual CAPEX | ~₹1,400 crores plus maintenance CAPEX, mainly for projects announced this financial year | FY26 |
| Favorable procurement environment | Continued price and supply stability expected | Next two quarters |
| Sea freight rates | Broadly stable | Q1 FY26 |
Key Metrics
| Metric | Q4 FY25 |
|---|---|
| Consolidated total income | ₹2,671 cr, vs ₹2,382 cr in Q4 FY24 |
| Profit before tax | ₹864 cr, vs ₹713 cr in Q4 FY24 |
| Profit after tax | ₹662 cr, vs ₹538 cr in Q4 FY24 |
| Forex gain | ₹10 cr gain, vs ₹2 cr loss in Q4 FY24 |
| Material consumption | ~40% of sales revenue, flat YoY |
| Constant currency growth (FY25) | 18%, vs negative 2% in FY24 |
| Export share of total sales (FY25) | ~88% |
| Europe and US share of total sales (FY25) | 73%, vs 70% in FY24 |
| Product mix: Generics vs Custom Synthesis | 49% / 51% |
| Nutraceutical revenue | ₹205 cr for the quarter; ₹781 cr for FY25 |
| Assets capitalized in the quarter | ₹560 cr, of which Kakinada project: ₹337 cr |
| Capital work-in-progress | ₹1,022 cr, of which Kakinada project: ₹562 cr |
| Total spent on Kakinada project to date | ₹1,497 cr (including assets capitalized and advances) |
| Cash on books | ₹3,696 cr |
| Receivables | ₹2,855 cr |
| Inventory | ₹3,033 cr |
| Other expenses as % of sales (FY25) | 14%, down from 17% in FY24 |
| EBITDA margin (FY25) | 32%, up from 29% in FY24 |
| Revenue growth guidance (FY26) | Double-digit growth |
| CAPEX planned for FY26 | ~₹1,400 cr plus maintenance CAPEX |
| Kakinada Phase-I additional CAPEX planned | ~₹200 cr |
| Commercialization timeline for new CS projects | Late 2026 to early 2027, subject to regulatory approvals |